Pharmacology can help buffer female heart disease patients from cutting funding

Coronary artery disease is one of the most important causes of death among American women. It is every third of death. Promoting age, as well as other contributing factors, significantly increase the risk of heart disease, while nearly seven in 10 women are accompanied by at least one such risk factor.

Unlike male heart disease, female heart disease usually affects arteries with smaller hearts and is therefore difficult to detect. Once the disease is discovered, this delay in recognition has a life-threatening effect on the treatment outcome. In addition, women experience mental stress chest pain more frequently than men. Furthermore, men suffer from chest pain more frequently, while women experience it from daily activities.

To address the impact on female heart disease patients, doctors can recommend virtual and preventive care platforms as well as AI tools. However, despite efforts to reduce the diagnosis differences between women compared to men (including presidential consultations from the American Heart Association), many women are treated before it is too late.

Cutting money can affect patients, pharmacogenomics can help

With federal funding cuts well, patients will feel the impact from cancer to heart disease research, especially underrepresented women in clinical trials, which is also a focus of drug research. In particular, less funding means that women can participate in fewer clinical trials and fewer potential treatment options. Therefore, better use of existing approved products, including AI options and drug genomic tools, can protect female heart patients from the negative effects of reduced funding.

Pharmacogenomics tools analyze patients’ unique genome profiles to understand which drugs can understand each person’s ability to metabolize drugs, which is best for that person. Rather than relying on trial responses for treatment, pharmacogenomics provides a tailored approach where doctors can use genomic data to develop a personalized treatment plan with the highest likelihood of success for each patient. In this regard, pharmacogenomic analysis provides the potential to help patients find successful treatments faster by matching them with drugs based on their genetics, rather than relying on general statistics about drug categories, which may not be applicable to a given patient based on their genomic characteristics.

Therefore, in federal research to cut women’s cardiology research, pharmacogenomics provides an opportunity to help shield female cardiology patients from certain negative effects by helping simplify the process from diagnosis to finding successful treatment for that patient.

Selecting pharmacogenomics tools for female cardiology patients

With several drug genomic tools on the market, doctors should evaluate each tool to see which features can best support patients. Some pharmacogenomics tools provide more comprehensive genetic analysis than others. For example, selecting the panels can analyze 22 guide genes from FDA, DPWG, and CPIC, including levels (a, a/b, b, and b/c), while other panels do not cover as many genes. Some drug genomic tools can even explore a 86-gene panel. With a panel targeting cardiology, psychiatry, pain management, rare diseases and primary care, doctors can consider which tool provides the right product for each patient.

Additionally, some tools run faster than others, changing the treatment schedule. It is worth noting that drug genomic platforms can take hours, or sometimes even just 25 minutes, to perform analysis. Of course, costs also play a role. Some products are priced higher, making cost a key factor in choice.

Additionally, the selected pharmacogenomics tool provides greater accuracy when selecting doses and medications. For example, some platforms validate their recommendations for 1,000 genomic projects, while some provide up to 97% Concorde. None of the error rate is zero, but doctors can choose the tool with margins they think are acceptable.

By turning to proven, fast, comprehensive pharmacogenomics tools, doctors can even continue to support their female cardiology patients in cutting federal funding for women’s cardiology research. Having tools that match patients with targeted treatment options can both shorten schedules and improve health outcomes.

Photo: Kiwi, Getty Images

This article passed Mixed Influencer program. Anyone can post a view on MedCity News' healthcare business and innovation through MedCity Remacence. Click here to learn how.